Visual Acuity Outcomes of the Boston Keratoprosthesis Type 1: Multicenter Study Results

Boston Type 1 Keratoprosthesis Study Group

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose To report logarithm of the minimal angle of resolution (logMAR) visual outcomes of the Boston keratoprosthesis type 1. Design Prospective cohort study. Methods Preoperative, intraoperative, and postoperative parameters of 300 eyes of 300 patients who underwent implantation of a Boston keratoprosthesis type 1 device between January 2003 and July 2008 by 1 of 19 surgeons at 18 medical centers were collected. Results After an average of 17.1 ± 14.8 months, visual acuity improved significantly (P <.0001) to a mean final value of 0.89 ± 0.64 (20/150). There were also significantly fewer eyes with light perception (6.7%; n = 19; P <.0001), although 3.1% (n = 9) progressed to no light perception. There was no association between age (P =.08), sex (P =.959), operative side (P =.167), or failure (P =.494) and final visual acuity. The median time to achieve 20/200 visual acuity was 1 month (95% confidence interval 1.0-6.0) and it was retained for an average of 47.8 months. Multivariate analysis, controlling for preoperative visual acuity, demonstrated 2 factors associated with final visual outcome: chemical injury was associated with better final vision (P =.007), whereas age-related macular degeneration was associated with poorer vision (P <.0001). Conclusions The Boston keratoprosthesis type 1 is an effective device for rehabilitation in advanced ocular surface disease, resulting in a significant improvement in visual acuity. Eyes achieved a mean value of 20/150 (0.89 ± 0.64 logMAR units) after 6 months and this was relatively stable thereafter. The best visual prognosis is observed in chemical injury eyes, whereas the worst prognosis is in aniridia, although the latter has limited visual potential.

Original languageEnglish (US)
Pages (from-to)89-98.e1
JournalAmerican journal of ophthalmology
Volume162
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Visual Acuity
Multicenter Studies
Aniridia
Eye Injuries
Light
Equipment and Supplies
Eye Diseases
Macular Degeneration
Cohort Studies
Rehabilitation
Multivariate Analysis
Prospective Studies
Confidence Intervals
Wounds and Injuries

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Visual Acuity Outcomes of the Boston Keratoprosthesis Type 1 : Multicenter Study Results. / Boston Type 1 Keratoprosthesis Study Group.

In: American journal of ophthalmology, Vol. 162, 01.02.2016, p. 89-98.e1.

Research output: Contribution to journalArticle

Boston Type 1 Keratoprosthesis Study Group. / Visual Acuity Outcomes of the Boston Keratoprosthesis Type 1 : Multicenter Study Results. In: American journal of ophthalmology. 2016 ; Vol. 162. pp. 89-98.e1.
@article{de538ace04db4a61a61d662653acf824,
title = "Visual Acuity Outcomes of the Boston Keratoprosthesis Type 1: Multicenter Study Results",
abstract = "Purpose To report logarithm of the minimal angle of resolution (logMAR) visual outcomes of the Boston keratoprosthesis type 1. Design Prospective cohort study. Methods Preoperative, intraoperative, and postoperative parameters of 300 eyes of 300 patients who underwent implantation of a Boston keratoprosthesis type 1 device between January 2003 and July 2008 by 1 of 19 surgeons at 18 medical centers were collected. Results After an average of 17.1 ± 14.8 months, visual acuity improved significantly (P <.0001) to a mean final value of 0.89 ± 0.64 (20/150). There were also significantly fewer eyes with light perception (6.7{\%}; n = 19; P <.0001), although 3.1{\%} (n = 9) progressed to no light perception. There was no association between age (P =.08), sex (P =.959), operative side (P =.167), or failure (P =.494) and final visual acuity. The median time to achieve 20/200 visual acuity was 1 month (95{\%} confidence interval 1.0-6.0) and it was retained for an average of 47.8 months. Multivariate analysis, controlling for preoperative visual acuity, demonstrated 2 factors associated with final visual outcome: chemical injury was associated with better final vision (P =.007), whereas age-related macular degeneration was associated with poorer vision (P <.0001). Conclusions The Boston keratoprosthesis type 1 is an effective device for rehabilitation in advanced ocular surface disease, resulting in a significant improvement in visual acuity. Eyes achieved a mean value of 20/150 (0.89 ± 0.64 logMAR units) after 6 months and this was relatively stable thereafter. The best visual prognosis is observed in chemical injury eyes, whereas the worst prognosis is in aniridia, although the latter has limited visual potential.",
author = "{Boston Type 1 Keratoprosthesis Study Group} and Rudnisky, {Christopher J.} and Belin, {Michael W.} and Rong Guo and Ciolino, {Joseph B.} and Dohlman, {C. H.} and J. Aquavella and Aldave, {A. J.} and Hannush, {S. B.} and Sippel, {K. C.} and Mannis, {M. J.} and Afshari, {N. A.} and Shen, {T. T.} and Alfonso, {Eduardo C} and Macsai, {M. S.} and G. Tabin and Baratz, {K. H.} and Hemady, {R. K.} and Abad, {J. C.} and Melki, {S. A.} and R. Pineda",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.ajo.2015.10.023",
language = "English (US)",
volume = "162",
pages = "89--98.e1",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Visual Acuity Outcomes of the Boston Keratoprosthesis Type 1

T2 - Multicenter Study Results

AU - Boston Type 1 Keratoprosthesis Study Group

AU - Rudnisky, Christopher J.

AU - Belin, Michael W.

AU - Guo, Rong

AU - Ciolino, Joseph B.

AU - Dohlman, C. H.

AU - Aquavella, J.

AU - Aldave, A. J.

AU - Hannush, S. B.

AU - Sippel, K. C.

AU - Mannis, M. J.

AU - Afshari, N. A.

AU - Shen, T. T.

AU - Alfonso, Eduardo C

AU - Macsai, M. S.

AU - Tabin, G.

AU - Baratz, K. H.

AU - Hemady, R. K.

AU - Abad, J. C.

AU - Melki, S. A.

AU - Pineda, R.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Purpose To report logarithm of the minimal angle of resolution (logMAR) visual outcomes of the Boston keratoprosthesis type 1. Design Prospective cohort study. Methods Preoperative, intraoperative, and postoperative parameters of 300 eyes of 300 patients who underwent implantation of a Boston keratoprosthesis type 1 device between January 2003 and July 2008 by 1 of 19 surgeons at 18 medical centers were collected. Results After an average of 17.1 ± 14.8 months, visual acuity improved significantly (P <.0001) to a mean final value of 0.89 ± 0.64 (20/150). There were also significantly fewer eyes with light perception (6.7%; n = 19; P <.0001), although 3.1% (n = 9) progressed to no light perception. There was no association between age (P =.08), sex (P =.959), operative side (P =.167), or failure (P =.494) and final visual acuity. The median time to achieve 20/200 visual acuity was 1 month (95% confidence interval 1.0-6.0) and it was retained for an average of 47.8 months. Multivariate analysis, controlling for preoperative visual acuity, demonstrated 2 factors associated with final visual outcome: chemical injury was associated with better final vision (P =.007), whereas age-related macular degeneration was associated with poorer vision (P <.0001). Conclusions The Boston keratoprosthesis type 1 is an effective device for rehabilitation in advanced ocular surface disease, resulting in a significant improvement in visual acuity. Eyes achieved a mean value of 20/150 (0.89 ± 0.64 logMAR units) after 6 months and this was relatively stable thereafter. The best visual prognosis is observed in chemical injury eyes, whereas the worst prognosis is in aniridia, although the latter has limited visual potential.

AB - Purpose To report logarithm of the minimal angle of resolution (logMAR) visual outcomes of the Boston keratoprosthesis type 1. Design Prospective cohort study. Methods Preoperative, intraoperative, and postoperative parameters of 300 eyes of 300 patients who underwent implantation of a Boston keratoprosthesis type 1 device between January 2003 and July 2008 by 1 of 19 surgeons at 18 medical centers were collected. Results After an average of 17.1 ± 14.8 months, visual acuity improved significantly (P <.0001) to a mean final value of 0.89 ± 0.64 (20/150). There were also significantly fewer eyes with light perception (6.7%; n = 19; P <.0001), although 3.1% (n = 9) progressed to no light perception. There was no association between age (P =.08), sex (P =.959), operative side (P =.167), or failure (P =.494) and final visual acuity. The median time to achieve 20/200 visual acuity was 1 month (95% confidence interval 1.0-6.0) and it was retained for an average of 47.8 months. Multivariate analysis, controlling for preoperative visual acuity, demonstrated 2 factors associated with final visual outcome: chemical injury was associated with better final vision (P =.007), whereas age-related macular degeneration was associated with poorer vision (P <.0001). Conclusions The Boston keratoprosthesis type 1 is an effective device for rehabilitation in advanced ocular surface disease, resulting in a significant improvement in visual acuity. Eyes achieved a mean value of 20/150 (0.89 ± 0.64 logMAR units) after 6 months and this was relatively stable thereafter. The best visual prognosis is observed in chemical injury eyes, whereas the worst prognosis is in aniridia, although the latter has limited visual potential.

UR - http://www.scopus.com/inward/record.url?scp=84959477486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959477486&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2015.10.023

DO - 10.1016/j.ajo.2015.10.023

M3 - Article

C2 - 26550696

AN - SCOPUS:84959477486

VL - 162

SP - 89-98.e1

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

ER -